Asia

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Friday, March 20, 2015

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

[Read More]

Daiichi Sankyo opens collaborative research and grants program

Friday, March 20, 2015

Daiichi Sankyo, a global pharmaceutical company based in Japan, has announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2015. The company will select research partners for the project from researchers based in Japan. TaNeDS was launched in 2011 and has since received numerous research theme proposals from across Japan, with various projects currently ongoing.

[Read More]

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

[Read More]

Sinovac’s EV71 vaccine produces positive phase III clinical trial results

Friday, February 28, 2014

Sinovac Biotech, a provider of biopharmaceutical products in China, has announced that Phase III clinical trial results for its proprietary Enterovirus 71 (EV71) vaccine have been published online in the February 27 issue of TheNew England Journal of Medicine (NEJM). The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease (HFMD), or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac’s vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.

[Read More]

Cytori, Lorem Vascular partner in Asia-Pacific

Wednesday, November 6, 2013

Cytori Therapeutics and Lorem Vascular, a Beijing-based provider of cardiovascular care, have announced a partnership to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia. Cytori Cell Therapy is derived from the company’s Celution System, which enables access to a patient’s own adipose-derived regenerative cells (ADRCs) at the point of care.

[Read More]

Hutchison MediPharma, Eli Lilly collaborate

Wednesday, October 16, 2013

Hutchison MediPharma (HMP), an R&D company majority owned by Chi-Med, has entered a licensing, co-development and commercialization agreement in China with Eli Lilly for Fruquintinib (HMPL-013), a targeted oncology therapy for the potential treatment of various types of solid tumors. Fruquintinib, a selective inhibitor of the Vascular Endothelial Growth Factor (“VEGF”) receptor tyrosine kinases, was discovered by HMP and currently is in phase II testing in China.  

[Read More]